Horita Y, Miyazaki M, Koji T, Kobayashi N, Shibuya M, Razzaque M S, Cheng M, Ozono Y, Kohno S, Taguchi T
Second Department of Pathology, Nagasaki University School of Medicine, Sakamoto, Japan.
Nephrol Dial Transplant. 1998 Oct;13(10):2519-28. doi: 10.1093/ndt/13.10.2519.
Based on the fact that vascular endothelial growth factor (VEGF) increases vascular permeability, it is speculated that VEGF might be involved in the development of proteinuria, although this remains unconfirmed. The production and site of action of VEGF remains unclear in nephrotic renal diseases.
Non-radioactive in situ hybridization was performed to examine the expression of VEGF mRNA and its receptors, flt-1 and KDR/flk-1, in a rat model of nephrosis induced by intraperitoneal injection of bovine serum albumin (BSA). Saline injected rats were served as control animals.
Neither morphological changes nor deposition of immunoglobulin or complement were observed in our model. Proteinuria developed, reaching a maximum level in rats injected with BSA for 3 days, followed by persistent proteinuria until day 14. The expression of mRNA for VEGF and the two receptors was markedly upregulated in glomeruli of BSA-induced nephritis compared with the control group. VEGF mRNA was localized in glomerular cells, including cells in mesangium, visceral and parietal epithelial cells. In contrast, flt-1 mRNA and KDR/flk-1 mRNA were expressed on glomerular endothelial cells and cells in mesangium. The ratio of glomerular cells positive for VEGF mRNA and its receptors mRNA increased proportionately with the severity of proteinuria. Immunohistochemistry for ED-1 and proliferating cell nuclear antigen showed no significant increase in infiltrating macrophage or cellular proliferation.
Our results suggest that altered glomerular expression of VEGF and its receptors is not associated with proliferation of endothelial cells, but rather with proteinuria in BSA-induced nephritis in rats. VEGF may play a different role in different renal diseases.
基于血管内皮生长因子(VEGF)可增加血管通透性这一事实,推测VEGF可能参与蛋白尿的发生,尽管这一点尚未得到证实。在肾病性肾脏疾病中,VEGF的产生及作用部位仍不清楚。
采用非放射性原位杂交技术检测腹腔注射牛血清白蛋白(BSA)诱导的大鼠肾病模型中VEGF mRNA及其受体flt-1和KDR/flk-1的表达。注射生理盐水的大鼠作为对照动物。
在我们的模型中未观察到形态学改变,也未发现免疫球蛋白或补体沉积。蛋白尿出现,在注射BSA 3天的大鼠中达到最高水平,随后持续蛋白尿直至第14天。与对照组相比,BSA诱导的肾炎大鼠肾小球中VEGF及其两种受体的mRNA表达明显上调。VEGF mRNA定位于肾小球细胞,包括系膜细胞、脏层和壁层上皮细胞。相比之下,flt-1 mRNA和KDR/flk-1 mRNA在肾小球内皮细胞和系膜细胞中表达。VEGF mRNA及其受体mRNA阳性的肾小球细胞比例随蛋白尿严重程度成比例增加。ED-1和增殖细胞核抗原的免疫组化显示浸润巨噬细胞或细胞增殖无明显增加。
我们的结果表明,VEGF及其受体在肾小球的表达改变与内皮细胞增殖无关,而是与大鼠BSA诱导的肾炎中的蛋白尿有关。VEGF在不同的肾脏疾病中可能发挥不同的作用。